Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aytu BioScience Inc.

aytubio.com

Latest From Aytu BioScience Inc.

US FDA Converges With Other Regulators On Insomnia Drug Warnings, But Broader Safety Disagreements Persist

US FDA will add boxed warnings to insomnia drugs, bringing it in line with other regulators, even as a study in JAMA Internal Medicine study indicates that national drug authorities often disagree more broadly over when to issue safety advisories.
Drug Safety FDA

Device/Diagnostics Quarterly Deal-Making Statistics, Q2 2017

Device and diagnostics fundraising slumped in Q2, but there was a substantial uptick in M&A activity. Device financings totaled just slightly over half of the previous quarter, while acquisitions grew almost six-fold, thanks primarily to Becton Dickinson's $23.5 billion play for CR Bard. Financing in diagnostics slid to $1.03 billion, less than half of Q1, whereas the $1.7 billion in M&As (most of that from PerkinElmer's $1.3 billion buy of EuroImmun) was more than double Q1's aggregate.

Medical Device In Vitro Diagnostics

Deal Watch: Merck KGAA, Pfizer, eFFECTOR Agree To PD-L1/MNK Combo Study In CRC

Recently approved Bavencio will be paired with experimental MNK1/2 inhibitor in microsatellite-stable colorectal cancer. CRO Parexel to go private, AbbVie teams with Principia in immunology R&D and more.

Deals M & A

Deals Shaping The Medical Industry, June 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2017.

Deals BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • In Vitro Diagnostics
    • Biosensors
    • Chemistry, Immunoassay
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Alias(es)
  • Rosewind Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Aytu BioScience Inc.
  • Senior Management
  • Josh Disbrow, CEO
    David Green, CFO
    Jarrett Disbrow, COO
  • Contact Info
  • Aytu BioScience Inc.
    Phone: (855) 298-8246
    373 Inverness Pkwy.
    Ste. 206
    Englewood, CO 80112
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register